Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis

NCT ID: NCT03093220

Last Updated: 2017-03-28

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-03-31
• Study Completion Date: 2018-12-31

Brief Summary

Community-acquired pneumonia (CAP) is a heterogeneous disease causing great morbidity, mortality and health care burden globally. Typing methods for discriminating different clinical conditions of the same disease are essential to a better management of CAP. Traditional typing systems based separately on clinical manifestations (such as PSI and CURB-65), pathogens(bacterial types, virulence, drug resistance, etc) or host immune state (immunocompetent, immunocompromised or immunodeficiency). Thus, they are barely able to represent the real disease status nor to precisely predict the mortality.

As the development of multi-omic technologies, the relatedness of different phenotypes at a molecular level have revolutionized our ability to differentiate among patients. Our study is aimed at establishing a novel molecular typing method of CAP. Multi-omic (including genomics, transcriptomes, and metabolisms) data obtained from enrolled CAP patients and isolated pathogens would be integrated analyzed and interpreted. Tthe investigators believe that an appropriate molecular typing method would lead to revolutionary changes in current arrangements of CAP.

Conditions

Respiratory Infections; Genetic Disorder; Community-Acquired Infections; Host-Pathogen Interactions

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

community-acquired pneumonia

all adult patients (aged \> 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• adult (aged > 16 years)
• diagnosed as community-acquired pneumonia

Exclusion Criteria

• being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy
• history of long-term nursing home stays
• history of recently hospitalized (<90 days)

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CapitalBio Group Corporation

UNKNOWN

Sponsor Role: collaborator

Chinese Academy of Sciences

OTHER_GOV

Sponsor Role: collaborator

West China Hospital

OTHER

Sponsor Role: collaborator

Second Hospital of Jilin University

OTHER

Sponsor Role: collaborator

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

Sponsor Role: collaborator

Peking University People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zhancheng Gao, Professor

Role: STUDY_CHAIR

Department of Respiratory Critical Care Medicine

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Yali Zheng, Dr

Role: CONTACT

drylzheng@gmail.com

15011451515 ext. 86

Facility Contacts

Yali Zheng, Dr

Role: primary

drylzheng@gmail.com

15011451515 ext. 86

References

Chen L, Xue J, Zhao L, He Y, Fu S, Ma X, Yu W, Tang Y, Wang Y, Gao Z. Lysophosphatidylcholine acyltransferase level predicts the severity and prognosis of patients with community-acquired pneumonia: a prospective multicenter study. Front Immunol. 2024 Jan 8;14:1295353. doi: 10.3389/fimmu.2023.1295353. eCollection 2023.

Reference Type: DERIVED

PMID: 38259459 (View on PubMed)

Yin L, Zhang Y, Zheng Y, Luo Q, Zhao L, Ni W, Xu Y, Gao Z. Early Detection of Aspergillus Species in Lower Respiratory Tract is Associated with Higher Mortality in Viral Community-Acquired Pneumonia: A Multicenter Prospective Cohort Study in China. Lung. 2023 Aug;201(4):387-396. doi: 10.1007/s00408-023-00638-2. Epub 2023 Jul 22.

Reference Type: DERIVED

PMID: 37480410 (View on PubMed)

Xie Y, Yu Y, Zhao L, Ning P, Luo Q, Zhang Y, Yin L, Zheng Y, Gao Z. Specific Cytokine Profiles Predict the Severity of Influenza A Pneumonia: A Prospectively Multicenter Pilot Study. Biomed Res Int. 2021 Oct 13;2021:9533044. doi: 10.1155/2021/9533044. eCollection 2021.

Reference Type: DERIVED

PMID: 34692846 (View on PubMed)

Chen L, Zhao L, Shang Y, Xu Y, Gao Z. Admission lysophosphatidylethanolamine acyltransferase level predicts the severity and prognosis of community-acquired pneumonia. Infection. 2021 Oct;49(5):877-888. doi: 10.1007/s15010-021-01585-x. Epub 2021 Mar 10.

Reference Type: DERIVED

PMID: 33694084 (View on PubMed)

Zheng Y, Ning P, Luo Q, He Y, Yu X, Liu X, Chen Y, Wang X, Kang Y, Gao Z. Inflammatory responses relate to distinct bronchoalveolar lavage lipidome in community-acquired pneumonia patients: a pilot study. Respir Res. 2019 May 2;20(1):82. doi: 10.1186/s12931-019-1028-8.

Reference Type: DERIVED

PMID: 31046764 (View on PubMed)

Luo Q, He X, Ning P, Zheng Y, Yang D, Xu Y, Shang Y, Gao Z. Admission Pentraxin-3 Level Predicts Severity of Community-Acquired Pneumonia Independently of Etiology. Proteomics Clin Appl. 2019 Jul;13(4):e1800117. doi: 10.1002/prca.201800117. Epub 2019 Feb 12.

Reference Type: DERIVED

PMID: 30557448 (View on PubMed)

Ning P, Zheng Y, Luo Q, Liu X, Kang Y, Zhang Y, Zhang R, Xu Y, Yang D, Xi W, Wang K, Chen Y, An S, Gao Z. Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity. Crit Care. 2018 May 14;22(1):130. doi: 10.1186/s13054-018-2049-2.

Reference Type: DERIVED

PMID: 29759075 (View on PubMed)

Luo Q, Ning P, Zheng Y, Shang Y, Zhou B, Gao Z. Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study. Crit Care. 2018 Jan 24;22(1):15. doi: 10.1186/s13054-018-1943-y.

Reference Type: DERIVED

PMID: 29368632 (View on PubMed)

Other Identifiers

2016YFC0903800

Identifier Type: -

Identifier Source: org_study_id